Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea R Redman

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Expert Opinion on Pharmacotherapy|December 19, 2003
Aggrenox((R)) versus other pharmacotherapy in preventing recurrent strokeAndrea R Redman, Gina J Ryan
Current Atherosclerosis Reports|June 8, 2002
Warfarin versus aspirin in the secondary prevention of stroke: the WARSS studyAndrea R Redman, LaWanda C Allen
The Annals of Pharmacotherapy|May 30, 2003
Chromium as adjunctive treatment for type 2 diabetesGina J Ryan, Nancy S Wanko, Andrea R Redman, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 20, 2004
CYP2C9 genetic polymorphisms and warfarinAndrea R Redman, Leslie J Dickmann, Robert S Kidd, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 27, 2007
Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapyAndrea R Redman, Jack Zheng, Shahab A Shamsi, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Expert Opinion on Pharmacotherapy|December 19, 2003
Aggrenox((R)) versus other pharmacotherapy in preventing recurrent strokeAndrea R Redman, Gina J Ryan
Current Atherosclerosis Reports|June 8, 2002
Warfarin versus aspirin in the secondary prevention of stroke: the WARSS studyAndrea R Redman, LaWanda C Allen
The Annals of Pharmacotherapy|May 30, 2003
Chromium as adjunctive treatment for type 2 diabetesGina J Ryan, Nancy S Wanko, Andrea R Redman, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 20, 2004
CYP2C9 genetic polymorphisms and warfarinAndrea R Redman, Leslie J Dickmann, Robert S Kidd, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 27, 2007
Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapyAndrea R Redman, Jack Zheng, Shahab A Shamsi, et al.
Pageof 1